StockNews.AI
ANRO
StockNews.AI
16 days

ANRO Investors Have the Opportunity to Lead the Alto Neuroscience Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

1. Faruqi & Faruqi is investigating claims against Alto Neuroscience (ANRO). 2. Allegations include misleading statements regarding ALTO-100's efficacy for MDD. 3. Alto's stock fell 69.99% after announcing clinical trial results on ALTO-100. 4. Analysts cut price targets significantly due to trial results' implications. 5. Investors have until September 19, 2025, to join the class action.

7m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in stock price following the trial results indicates extreme investor loss of confidence, similar to past pharmaceutical failures impacting valuation heavily.

How important is it?

The lawsuit's nature and recent trial results have immediate and severe implications for ANRO's market price.

Why Short Term?

The immediate impact from the trial results and ongoing legal investigations will influence investor perception and stock performance in the near term.

Related Companies

PFEJNJMRNABMY
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their OptionsIf you purchased or otherwise acquired stock of Alto (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, 2024 (the "IPO" or "Offering"); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information], /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and reminds investors of the September 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) ALTO-100 was less effective in treating MDD than Defendants had led investors to believe; (2) accordingly, ALTO-100's clinical, regulatory, and commercial prospects were overstated; (3) as a result, Alto's business and/or financial prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times. On October 22, 2024, Alto issued a press release announcing topline results from the Phase 2b trial evaluating ALTO-100 as a treatment for MDD. That press release stated, in relevant part, that "ALTO-100 in patients with [MDD] did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo."On this news, Alto's stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.Analysts were quick to comment on the Company's announcement. For example, on October 22, 2024, Jeffries cut its price target for Alto to $17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry.The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Alto's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.To learn more about the Alto Neuroscience class action, go to www.faruqilaw.com/ANRO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.SOURCE Faruqi & Faruqi, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News